Bone Biologics (NASDAQ:BBLG) Posts Earnings Results, Beats Expectations By $0.11 EPS

Bone Biologics (NASDAQ:BBLG) released its quarterly earnings data on Thursday. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.11, FiscalAI reports.

Bone Biologics Stock Performance

Shares of Bone Biologics stock opened at $1.29 on Friday. The firm has a market cap of $2.31 million, a PE ratio of -0.57 and a beta of 0.89. The firm’s 50-day simple moving average is $1.26 and its 200-day simple moving average is $1.50. Bone Biologics has a 1 year low of $1.05 and a 1 year high of $6.75.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Bone Biologics has a consensus rating of “Sell”.

Institutional Investors Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC increased its holdings in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the quarter. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. Institutional investors own 34.30% of the company’s stock.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.